ES2129048T3 - Composicion estabilizada de hormona paratiroide. - Google Patents

Composicion estabilizada de hormona paratiroide.

Info

Publication number
ES2129048T3
ES2129048T3 ES92924889T ES92924889T ES2129048T3 ES 2129048 T3 ES2129048 T3 ES 2129048T3 ES 92924889 T ES92924889 T ES 92924889T ES 92924889 T ES92924889 T ES 92924889T ES 2129048 T3 ES2129048 T3 ES 2129048T3
Authority
ES
Spain
Prior art keywords
parathyroid hormone
stabilized composition
pth
stabilized
stabilizers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92924889T
Other languages
English (en)
Inventor
Ken - Daiba Endo
Shinji Sato
Yoshinori Sugiyama
Masaru Ohno
Hideo Sakakibara
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Asahi Kasei Corp
Asahi Chemical Industry Co Ltd
Original Assignee
Asahi Chemical Industry Co Ltd
Asahi Kasei Kogyo KK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP4313381A external-priority patent/JP2662842B2/ja
Application filed by Asahi Chemical Industry Co Ltd, Asahi Kasei Kogyo KK filed Critical Asahi Chemical Industry Co Ltd
Application granted granted Critical
Publication of ES2129048T3 publication Critical patent/ES2129048T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone (parathormone); Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Abstract

UN PREPARADO LIOFILIZADO ESTABILIZADO, ALTAMENTE SEGURO DE UNA HORMONA PARATIROIDES (PTH) QUE CONTIENE PTH COMO EL INGREDIENTE ACTIVO Y CANTIDADES EFECTIVAS DE UN AZUCAR Y CLORURO DE SODIO COMO LOS ESTABILIZADORES PARA EL PTH.
ES92924889T 1991-12-09 1992-12-08 Composicion estabilizada de hormona paratiroide. Expired - Lifetime ES2129048T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP35023691 1991-12-09
JP4313381A JP2662842B2 (ja) 1991-12-09 1992-11-24 パラサイロイドホルモンの安定化組成物

Publications (1)

Publication Number Publication Date
ES2129048T3 true ES2129048T3 (es) 1999-06-01

Family

ID=26567535

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92924889T Expired - Lifetime ES2129048T3 (es) 1991-12-09 1992-12-08 Composicion estabilizada de hormona paratiroide.

Country Status (7)

Country Link
US (1) US5563122A (es)
EP (1) EP0619119B1 (es)
KR (1) KR0131678B1 (es)
AU (1) AU3095092A (es)
DE (1) DE69228828T2 (es)
ES (1) ES2129048T3 (es)
WO (1) WO1993011785A1 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT679088E (pt) 1992-09-29 2002-12-31 Inhale Therapeutic Syst Administracao pulmonar de fragmentos activos de hormona paratiroide
IT1255723B (it) * 1992-10-09 1995-11-13 Uso di paratormone,suoi frammenti biologicamente attivi e peptidi correlati, per la preparazione di composizioni farmaceutiche utili nella prevenzione e terapia dell'aborto e del parto pretermine ed in generale per il trattamento della gestazione
US5496801A (en) * 1993-12-23 1996-03-05 Allelix Biopharmaceuticals Inc. Parathyroid hormone formulation
US6290991B1 (en) 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
DE19538687A1 (de) * 1995-10-17 1997-04-24 Boehringer Mannheim Gmbh Stabile pharmazeutische Darreichungsformen enthaltend Parathormon
SE9604795D0 (sv) * 1996-12-20 1996-12-20 Astra Pharma Prod New pharmaceutical formulation
SE9702401D0 (sv) 1997-06-19 1997-06-19 Astra Ab Pharmaceutical use
SE9702680D0 (sv) * 1997-07-11 1997-07-11 Astra Pharma Prod New formulation
US6770623B1 (en) * 1997-12-09 2004-08-03 Eli Lilly And Company Stabilized teriparatide solutions
MY120063A (en) * 1997-12-09 2005-08-30 Lilly Co Eli Stabilized teriparatide solutions
SE9801495D0 (sv) * 1998-04-28 1998-04-28 Astra Ab Protein formulationa
US7893021B2 (en) * 1999-06-02 2011-02-22 Scantibodies Laboratory, Inc. Parathyroid hormone antagonists and uses thereof
US20080108086A1 (en) * 1999-06-02 2008-05-08 Cantor Thomas L Parathyroid hormone antagonists and uses thereof
US6573092B1 (en) * 2000-10-10 2003-06-03 Genvec, Inc. Method of preparing a eukaryotic viral vector
US20050032698A1 (en) * 2003-07-14 2005-02-10 Nps Allelix Corp. Stabilized formulation of parathyroid hormone
AU2005244734A1 (en) 2004-05-13 2005-12-01 Alza Corporation Apparatus and method for transdermal delivery of parathyroid hormone agents
CN101189031A (zh) * 2005-06-02 2008-05-28 阿尔扎公司 透皮递送器械的最终消毒方法
KR100700869B1 (ko) * 2005-06-03 2007-03-29 재단법인 목암생명공학연구소 Ｐｔｈ, 완충제 및 안정제를 포함하는 안정한 ｐｔｈ조성물
US8173385B2 (en) * 2005-07-20 2012-05-08 Kyowa Medex Co., Ltd. Method for stabilization of peptides in a biological sample
CN101466393A (zh) * 2006-03-15 2009-06-24 阿尔扎公司 用于经皮递送甲状旁腺激素药剂以治疗骨质减少的方法
EP1961765A1 (en) * 2006-12-08 2008-08-27 Zealand Pharma A/S Truncated PTH peptides with a cyclic conformation
US8613951B2 (en) 2008-06-16 2013-12-24 Bind Therapeutics, Inc. Therapeutic polymeric nanoparticles with mTor inhibitors and methods of making and using same
EP2309990B2 (en) 2008-06-16 2017-03-15 Pfizer Inc. Drug loaded polymeric nanoparticles and methods of making and using same
ES2721850T3 (es) 2008-06-16 2019-08-05 Pfizer Nanopartículas poliméricas terapéuticas que comprenden alcaloides vinca y procedimientos de fabricación y uso de las mismas
US8563041B2 (en) 2008-12-12 2013-10-22 Bind Therapeutics, Inc. Therapeutic particles suitable for parenteral administration and methods of making and using same
JP2012512175A (ja) 2008-12-15 2012-05-31 バインド バイオサイエンシズ インコーポレイテッド 治療薬を徐放するための長時間循環性ナノ粒子
US8357401B2 (en) 2009-12-11 2013-01-22 Bind Biosciences, Inc. Stable formulations for lyophilizing therapeutic particles
ES2780156T3 (es) 2009-12-15 2020-08-24 Pfizer Composiciones terapéuticas de nanopartículas poliméricas con alta temperatura de transición vítrea o copolímeros de alto peso molecular
KR20140001255A (ko) 2011-06-07 2014-01-06 아사히 가세이 파마 가부시키가이샤 고순도 ｐｔｈ 함유 동결 건조 제제 및 그의 제조 방법
BR112015005940A2 (pt) 2012-09-17 2017-07-04 Bind Therapeutics Inc processo para a preparação de nanopartículas terapêuticas
MX2016012009A (es) 2014-03-14 2016-12-05 Pfizer Nanoparticulas terapeuticas que comprenden un agente terapeutico, y metodos para su elaboracion y uso.
CN106309358A (zh) * 2015-06-29 2017-01-11 成都金凯生物技术有限公司 含有人甲状旁腺激素的药物组合物及其制备方法与用途
CN115279396A (zh) * 2020-03-30 2022-11-01 四川泸州步长生物制药有限公司 人类甲状旁腺激素(pth)的制剂及用于生产其的方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4806343A (en) * 1986-03-13 1989-02-21 University Of Southwestern Louisiana Cryogenic protectant for proteins
JPS6360940A (ja) * 1986-09-01 1988-03-17 Toyo Jozo Co Ltd 白内障の予防または治療剤
JPH022233A (ja) * 1988-06-14 1990-01-08 Fujitsu Ltd データバス監視方式
JPH0610138B2 (ja) * 1988-07-12 1994-02-09 日本化薬株式会社 スーパーオキシドディスムターゼ組成物
JPH0341033A (ja) * 1989-07-07 1991-02-21 Kyowa Hakko Kogyo Co Ltd 安定なモチリン類含有製剤
GB9020544D0 (en) * 1990-09-20 1990-10-31 Sandoz Ltd Improvements in or relating to organic compounds
EP0499990B1 (en) * 1991-02-19 1996-05-15 Takeda Chemical Industries, Ltd. Method for producing cysteine-free peptides
US5344644A (en) * 1991-08-01 1994-09-06 Takeda Chemical Industries, Ltd. Water-soluble composition for sustained-release
US5496801A (en) * 1993-12-23 1996-03-05 Allelix Biopharmaceuticals Inc. Parathyroid hormone formulation

Also Published As

Publication number Publication date
EP0619119A1 (en) 1994-10-12
EP0619119A4 (en) 1995-07-12
AU3095092A (en) 1993-07-19
DE69228828D1 (de) 1999-05-06
EP0619119B1 (en) 1999-03-31
DE69228828T2 (de) 1999-12-16
US5563122A (en) 1996-10-08
KR0131678B1 (ko) 1998-04-17
WO1993011785A1 (en) 1993-06-24

Similar Documents

Publication Publication Date Title
ES2129048T3 (es) Composicion estabilizada de hormona paratiroide.
MX9202407A (es) Composicion farmaceutica que contiene un compuesto de alilamina como el agente activo y proceso para su preparacion.
ES2088312T3 (es) Formulacion de liberacion controlada que contiene tramadol.
DE19375061I2 (de) Hexadecylphosphocolin enthaltende arzneimittel mit antitumorwirkung.
MX9202328A (es) Composicion farmaceutica local que contiene un compuesto alilamina como el agente activo.
AR240225A1 (es) Composicion insecticida que comprende mas de un compuesto activo.
ES531978A0 (es) Un procedimiento para preparar composiciones farmaceuticas de disolucion rapida que contienen como ingrediente activo triamteremo o metolazona.
DK358384D0 (da) Farmaceutiske midler til bekaempelse af diabetes mellitus
ES2063033T3 (es) Empleo de igf-ii en el tratamiento de la enfermedades de los huesos.
IT1190824B (it) Composizione farmaceutica contenente 24,25-diidrossicolecalciferolo come ingrediente attivo
AR001738A1 (es) Preparados en forma de capsulas para el tratamiento de plantas y método para administrar compuestos biologicamente activos a plantas
ES2076595T3 (es) Derivados de amidinofenilalanina, procedimiento para su preparacion, su empleo y agentes que los contienen.
ECSP930933A (es) Composicion farmaceutica y procedimiento para prepararla
MX24039A (es) Composiciones farmaceuticas que contienen una calcitonina como principio activo.
AR005970A1 (es) Compuestos de benzotiofeno y formulaciones farmaceuticas que los contienen como agente activo
NO985571L (no) Legemiddel for autoimmunsykdommer
DK0469440T3 (da) Faste orale applikationsformer, der som aktivt stof indeholder ifosamid
CO4830457A1 (es) Preparados efervescentes
GB2021409A (en) Pharmaceutical composition
ES2053535T3 (es) Derivados heterociclicos de cinco miembros de n,n'-diacilhidrazinas n' sustituidas.
ES2046246T3 (es) Composicion terapeutica para combatir el sida.
JPS5366420A (en) Insecticide against maggots
DE3573707D1 (de) Anticoccidial compostions
ES2033181B1 (es) Una tableta o capsula de herbicida para su aplicacion en arrozales.
ES2083490T3 (es) 3,5-diyodo-l-tironina para la supresion de tsh y el tratamiento del bocio.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 619119

Country of ref document: ES